Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

被引:22
|
作者
Evans, Elizabeth A. [1 ]
Yoo, Caroline [2 ]
Huang, David [2 ]
Saxon, Andrew J. [3 ]
Hser, Yih-Ing [2 ]
机构
[1] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Promot & Policy, 312 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA
[2] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, 11075 Santa Monica Blvd,Ste 200, Los Angeles, CA 90024 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA
关键词
Buprenorphine; Treatment acceptability; access; and utilization; Opioid use disorder; Pharmacotherapy; Longitudinal; MAINTENANCE TREATMENT; PATIENT PERSPECTIVES; METHADONE TREATMENT; ADDICTION; DEPENDENCE; RETENTION; OUTCOMES; MORTALITY; ABUSE; FACILITIES;
D O I
10.1016/j.jsat.2019.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Nationwide efforts seek to address the opioid epidemic by increasing access to medications for opioid use disorder (OUD), particularly with buprenorphine. A poorly understood challenge is that among individuals with OUD who do receive buprenorphine, many do not adhere to the pharmacotherapy long enough to achieve sustained benefits. We aimed to identify factors associated with buprenorphine treatment utilization over time. Methods: We used random-intercept modeling to identify factors associated with buprenorphine treatment utilization over 2 years after first follow-up by 789 individuals with OUD who had participated in a multi-site randomized clinical trial of buprenorphine compared to methadone. Key predictors were participants' reports of buprenorphine treatment accessibility and acceptability (assessed at first follow-up) and their interaction effects, controlling for baseline randomization status, sociodemographics, and other covariates. Results: Approximately 9.3-11.2% of participants utilized buprenorphine treatment over the 2 years of follow-up. Interaction effects indicated that individuals who perceived buprenorphine to be both accessible and acceptable were most likely to use buprenorphine during follow-up, controlling for other factors. In contrast, individuals who perceived buprenorphine to be unacceptable were least likely to use buprenorphine, regardless the level of perceived access to the medication. Buprenorphine treatment utilization was also negatively associated with Hispanic ethnicity, West coast context, and cumulative months receiving methadone treatment and incarceration during follow-up. Conclusions: To engage more individuals with OUD in long-term treatment with buprenorphine, interventions should target buprenorphine treatment acceptability, in addition to increasing buprenorphine access, and tailor efforts to meet the needs of vulnerable populations.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 36 条
  • [1] Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone
    Zhu, Yuhui
    Mooney, Larissa J.
    Yoo, Caroline
    Evans, Elizabeth A.
    Kelleghan, Annemarie
    Saxon, Andrew J.
    Curtis, Megan E.
    Hser, Yih-Ing
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228
  • [2] Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder
    Evans, Elizabeth A.
    Zhu, Yuhui
    Yoo, Caroline
    Huang, David
    Hser, Yih-Ing
    ADDICTION, 2019, 114 (08) : 1396 - 1404
  • [3] Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder
    Samuel C. Peter
    James G. Murphy
    Katie Witkiewitz
    Sarah B. Hand
    Fridtjof Thomas
    Karen Chandler Johnson
    Ronald Cowan
    Matt Harris
    Karen J. Derefinko
    Trials, 24
  • [4] Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder
    Peter, Samuel C. C.
    Murphy, James G. G.
    Witkiewitz, Katie
    Hand, Sarah B. B.
    Thomas, Fridtjof
    Johnson, Karen Chandler
    Cowan, Ronald
    Harris, Matt
    Derefinko, Karen J. J.
    TRIALS, 2023, 24 (01)
  • [5] Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial
    Polsky, Daniel
    Glick, Henry A.
    Yang, Jianing
    Subramaniam, Geetha A.
    Poole, Sabrina A.
    Woody, George E.
    ADDICTION, 2010, 105 (09) : 1616 - 1624
  • [6] Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial
    McAnulty, Christina
    Bastien, Gabriel
    Ledjiar, Omar
    Socias, M. Eugenia
    Le Foll, Bernard
    Lim, Ron
    Jutras-Aswad, Didier
    ADDICTIVE BEHAVIORS, 2024, 154
  • [7] Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence A 2-Phase Randomized Controlled Trial
    Weiss, Roger D.
    Potter, Jennifer Sharpe
    Fiellin, David A.
    Byrne, Marilyn
    Connery, Hilary S.
    Dickinson, William
    Gardin, John
    Griffin, Margaret L.
    Gourevitch, Marc N.
    Haller, Deborah L.
    Hasson, Albert L.
    Huang, Zhen
    Jacobs, Petra
    Kosinski, Andrzej S.
    Lindblad, Robert
    McCance-Katz, Elinore F.
    Provost, Scott E.
    Selzer, Jeffrey
    Somoza, Eugene C.
    Sonne, Susan C.
    Ling, Walter
    ARCHIVES OF GENERAL PSYCHIATRY, 2011, 68 (12) : 1238 - 1246
  • [8] Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder A Randomized Clinical Trial
    Lofwall, Michelle R.
    Walsh, Sharon L.
    Nunes, Edward V.
    Bailey, Genie L.
    Sigmon, Stacey C.
    Kampman, Kyle M.
    Frost, Michael
    Tiberg, Fredrik
    Linden, Margareta
    Sheldon, Behshad
    Oosman, Sonia
    Peterson, Stefan
    Chen, Michael
    Kim, Sonnie
    JAMA INTERNAL MEDICINE, 2018, 178 (06) : 764 - 773
  • [9] A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder
    Jones, Jermaine D.
    Campbell, Aimee N.
    Brandt, Laura
    Metz, Verena E.
    Martinez, Suky
    Wall, Melanie
    Corbeil, Thomas
    Andrews, Howard
    Castillo, Felipe
    Neale, Joanne
    Strang, John
    Ross, Stephen
    Comer, Sandra D.
    DRUG AND ALCOHOL DEPENDENCE, 2022, 237
  • [10] A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder
    Jones, Jermaine D.
    Campbell, Aimee N.
    Brandt, Laura
    Metz, Verena E.
    Martinez, Suky
    Wall, Melanie
    Corbeil, Thomas
    Andrews, Howard
    Castillo, Felipe
    Neale, Joanne
    Strang, John
    Ross, Stephen
    Comer, Sandra D.
    DRUG AND ALCOHOL DEPENDENCE, 2022, 237